Literature DB >> 15081432

Inhibition of human P450 enzymes by nicotinic acid and nicotinamide.

Cédric Gaudineau1, Karine Auclair.   

Abstract

Nicotinic acid has been used as a cholesterol-lowering agent for a few decades already, whereas the cytoprotective and antiviral properties of nicotinamide are slowly gaining attention. In both cases however, very high doses are needed to achieve a therapeutic effect, resulting in blood concentrations sometimes as high as 15 mM. Based on their common pyridine functionality, we hypothesized that these two molecules could inhibit human P450 enzymes. In vitro inhibition studies demonstrate that, at their therapeutic concentrations, both nicotinic acid and nicotinamide inhibit CYP2D6 (Ki = 3.8 +/- 0.3 and 19 +/- 4 mM, respectively). Nicotinamide also inhibits CYP3A4 (Ki = 13 +/- 3 mM) and CYP2E1 (Ki = 13 +/- 8 mM). As expected for nitrogen-containing heteroaromatic molecules, spectrophotometric analysis indicates that the inhibition occurs via coordination of the pyridine nitrogen atom to the heme iron.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081432     DOI: 10.1016/j.bbrc.2004.03.137

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 2.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

3.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

Review 4.  Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide.

Authors:  Faqi Li; Zhao Zhong Chong; Kenneth Maiese
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 5.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 6.  New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.

Authors:  Kenneth Maiese
Journal:  Front Biosci (Landmark Ed)       Date:  2020-06-01

7.  N-[(2S)-2-(4-Bromo-phen-yl)-4-oxo-1,3-thia-zolidin-3-yl]pyridine-3-carboxamide.

Authors:  Mehmet Akkurt; Ismail Celik; Hale Demir; Sumru Ozkırımlı; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-18

8.  N-[2-(4-Chloro-phen-yl)-5-methyl-4-oxo-1,3-thia-zolidin-3-yl]pyridine-3-carboxamide.

Authors:  Mehmet Akkurt; Ismail Celik; Hale Demir; Sumru Ozkırımlı; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-03-02

Review 9.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

Review 10.  Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2021       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.